Skip to main content
Caplight Logo









Curi Bio

Curi Bio

Private
Seattle, WashingtonHealthcare & Life Scienceshttps://www.curibio.com/

Last Round

Series B

Dec 2, 2025

Total Funding Raised

$24.4M

Momentum

Top 50%

of companies Caplight tracks

Company Overview

Curi Bio is a biotechnology company that provides a preclinical discovery platform combining human stem cells, systems, and data to accelerate the discovery of new medicines.

Sector

Healthcare & Life Sciences

Verticals

Drug Discovery, Biotechnology, Biotech Equipment, Medical Devices

Business Model

B2B

Customer Profile

Hardware Sales, Services & Consulting, Subscription SaaS, Data as a Service

AI Layer

Application

Keywords

drug discoveryiPSCinduced pluripotent stem celltissue engineeringorgan-on-a-chippreclinical testing3D muscle tissuecontractile force measurementphenotypic screeningbiotech equipmenthigh-throughput screeningelectrophysiologycontract researchlab automationassay development

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Curi Bio Comparables

Compare Curi Bio with similar companies based on industry and business-model similarity.

Curi Bio comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
MIMETAS
87%
CN Bio
82%
Emulate
82%

Curi Bio Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series BDec 2, 2025
GrantAug 23, 2023
Series ADec 29, 2021

Key People

Founding team and executive leadership

Nicholas Geisse

Chief Executive Officer

Executive Team

Dongwook Kim

Chief Financial Officer

Executive Team

Curi Bio Investors

Notable investors and investment history

Curi Bio investors
InvestorRounds
Dynamk CapitalSeries A
UTC InvestmentSeries B, Series A
NIH RADxGrant
DS Asset ManagementSeries B, Series A
National Center for Advancing Translational SciencesGrant

Market signals

Structured signals derived from secondary market and firmographic data.

  • Mar 23, 2026

    Launched a commercially available HCM isogenic pair.

  • Mar 20, 2026

    Partnered with Battelle to commercialize NMJ assay technology.

Curi Bio Filings

Explore SEC and related filing metadata, where available.

Curi Bio filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Curi Bio's valuation, stock price, and market status.

Is Curi Bio a public or private company?

Curi Bio is a private company.

What is the current stock price of Curi Bio?

Curi Bio is a private company with no public stock price. No recent secondary market data is available.

How much is Curi Bio worth (valuation)?

Valuation information for Curi Bio is not publicly available.

Can I buy Curi Bio stock?

Curi Bio shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Curi Bio's last funding round?

Curi Bio's most recent funding round was Series B on December 2, 2025.

Who are the main investors in Curi Bio?

Key investors in Curi Bio include Dynamk Capital, NIH RADx.

Will Curi Bio IPO soon?

No public IPO plans have been announced for Curi Bio.

How can I track Curi Bio secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Curi Bio's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersSeattle, Washington
Employee Range44
Year Founded2015
Last FundingDec 2, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?